Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

SAN JOSE, Calif., July 27, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance…

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks